PET Imaging Effective for Managing Pediatric Cancer Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

TORONTO, Canada-Positron emission tomography (PET) proved superior to both CT and MRI for both diagnosis and therapeutic monitoring of pediatric cancer patients in a study conducted at the University of Munich. Ute Porn, Jr., MD, described the results at the 48th Annual Meeting of the Society of Nuclear Medicine (abstract 144).

TORONTO, Canada—Positron emission tomography (PET) proved superior to both CT and MRI for both diagnosis and therapeutic monitoring of pediatric cancer patients in a study conducted at the University of Munich. Ute Porn, Jr., MD, described the results at the 48th Annual Meeting of the Society of Nuclear Medicine (abstract 144).

PET assesses the rate of cellular metabolism in tumors by determining the rate of uptake of radiolabeled fluorodeoxyglucose (FDG), an analog of glucose. In PET scans, cancerous tumors show up more brightly than noncancerous tissues. This selectivity, indicative of a higher rate of glucose usage, reflects the fact that cancer cells usually have a higher metabolic rate than nonmalignant cells.

Dr. Porn and her colleagues examined a total of 63 PET scans in 42 children, aged 1 to 17, with known or suspected tumors. Diagnoses from the imaging techniques were then confirmed by histopathology, clinical follow-up, or both.

While all the patients had cancer at some point, in this study some were investigated after chemotherapy/radiotherapy and/or surgery, so that in many instances no recurrent tumor would have been expected.

Overall, PET proved equal to or better than the other imaging techniques in both sensitivity and specificity, and was especially superior in specificity, ie, in avoiding diagnoses of cancer where none was present.

Moreover, in discussing the results, Dr. Porn indicated that PET was also better than CT or MRI in delineating scar tissue from residual tumors, and showed good correlation between post-therapeutic radioactive uptake and response of the tumor to treatment.

The one false-positive PET reading reflected enhanced FDG uptake by muscle, a tissue known to be highly active metabolically, while the false-negative readings resulted either from particularly small tumors or from tumors whose glucose metabolism proved to be lower than is typically observed in cancerous cells.

While still a relatively rare condition, cancer remains the leading cause of death in children under 15, with about 8,600 cases and 1,500 deaths expected this year in the United States, according to the American Cancer Society. Given the continued importance of early detection, it is essential that the advantages provided by PET be made as widely available as possible, Dr. Porn commented. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video